Interims results show a strong improvement in margins and cash generation as a result of self-help measures and strong execution from management taking effect. The outlook remains positive, with H2 looking well underpinned by orders already received in the Point-of-Care division and further growth from the newly commissioned Life Sciences manufacturing plant in South Bend. We make no changes to our forecasts at this stage and flag the mid-teens EBITDA growth outlook and attractive earnings multi ....
